Empagliflozin PBS population expanded

AJP Staff 28/10/2025

Eligible patients more than doubled in line with largest trial on SGLT-2 inhibitors in CKD The PBS listing of Jardiance (empagliflozin 10mg) will be significantly expanded to include a broader group of patients with chronic kidney disease (CKD), both with and without albuminuria. From 1 November, the PBS listing will be expanded to include more

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

Empagliflozin PBS population expanded

Previous Butler backs sunscreen safety

Next October MIMS Update

MENU

ajp.com.au

Previous Butler backs sunscreen safety

Next October MIMS Update

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.